The therapeutic potential of anti-HMGB1 antibody, soluble RAGE, and anti-RAGE neutralizing antibody has been demonstrated in experimental sepsis [73, 74], liver ischemia/reperfusion injury [75], Con-A-induced hepatic injury [76], traumatic brain injury [77], and organ transplantation [78, 79]. This evidence concerns the gene HMGB1 and Sepsis.